Frontline treatment of acute myeloid leukemia in adults

Appelbaum, 2006, Age and acute myeloid leukemia, Blood, 107, 3481, 10.1182/blood-2005-09-3724 Appelbaum, 2006, The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations, Br. J. Haematol., 135, 165, 10.1111/j.1365-2141.2006.06276.x Araki, 2016, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?, J. Clin. Oncol., 34, 329, 10.1200/JCO.2015.63.3826 Aribi, 2007, Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia, Cancer, 109, 1355, 10.1002/cncr.22524 Büchner, 2009, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group, J. Clin. Oncol., 27, 61, 10.1200/JCO.2007.15.4245 Barba, 2010, Biol. Blood Marrow Transpl., 16, 413, 10.1016/j.bbmt.2009.11.008 Basara, 2009, Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission, Leukemia, 23, 635, 10.1038/leu.2008.352 Becker, 2015, G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm, Am. J. Hematol., 90, 295, 10.1002/ajh.23927 Bennett, 1976, Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group, Br. J. Haematol., 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Bennett, 1985, Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group, Ann. Intern. Med., 103, 620, 10.7326/0003-4819-103-4-620 Bertoli, 2013, Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia, Blood, 121, 2618, 10.1182/blood-2012-09-454553 Bierenbaum, 2012, Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience, Leuk. Res., 36, 140, 10.1016/j.leukres.2011.10.018 Bloomfield, 1998, Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype, Cancer Res., 58, 4173 Borthakur, 2008, Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival, Cancer, 113, 3181, 10.1002/cncr.23927 Borthakur, 2014, Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia, Am. J. Hematol., 89, 964, 10.1002/ajh.23795 Breccia, 2011, Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy, Expert Opin. Biol. Ther., 11, 225, 10.1517/14712598.2011.543895 Bullinger, 2008, An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML, Blood, 111, 4490, 10.1182/blood-2007-09-115055 Burnett, 2007, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment, Cancer, 109, 1114, 10.1002/cncr.22496 Burnett, 2011, Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial, J. Clin. Oncol., 29, 369, 10.1200/JCO.2010.31.4310 Burnett, 2013, Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial, J. Clin. Oncol., 31, 3360, 10.1200/JCO.2012.47.4874 Burnett, 2015, A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, Blood, 125, 3878, 10.1182/blood-2015-01-623447 Byrd, 2002, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461), Blood, 100, 4325, 10.1182/blood-2002-03-0772 Byrd, 2004, Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461, J. Clin. Oncol., 22, 1087, 10.1200/JCO.2004.07.012 Care, 2003, Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias, Br. J. Haematol., 121, 775, 10.1046/j.1365-2141.2003.04362.x Chen, 2011, Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation, J. Clin. Oncol., 29, 2507, 10.1200/JCO.2010.34.2873 Chen, 2015, Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia, J. Clin. Oncol., 33, 1258, 10.1200/JCO.2014.58.3518 Ciurea, 2015, Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia, Blood, 126, 1033, 10.1182/blood-2015-04-639831 Coombs, 2015, Acute promyelocytic leukemia: where did we start, where are we now, and the future, Blood Cancer J., 5, e304, 10.1038/bcj.2015.25 Cornelissen, 2007, Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?, Blood, 109, 3658, 10.1182/blood-2006-06-025627 Cortes, 1994, All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia, Cancer, 73, 2946, 10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-Q Cortes, 2013, Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status, J. Clin. Oncol., 31, 3681, 10.1200/JCO.2013.48.8783 Döhner, 2002, Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm, J. Clin. Oncol., 20, 3254, 10.1200/JCO.2002.09.088 Döhner, 2005, Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood, 106, 3740, 10.1182/blood-2005-05-2164 Döhner, 2010, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, 115, 453, 10.1182/blood-2009-07-235358 Döhner, 2007, Implication of the molecular characterization of acute myeloid leukemia, Hematol. Am. Soc. Hematol. Educ. Program, 412, 10.1182/asheducation-2007.1.412 Daver, 2013, Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy, Clin. Lymphoma Myeloma Leuk., 13, 435, 10.1016/j.clml.2013.02.021 Daver, 2014, Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS), Blood, 124 Daver, 2015, Secondary mutations as mediators of resistance to targeted therapy in leukemia, Blood, 125, 3236, 10.1182/blood-2014-10-605808 DeSantis, 2014, Cancer treatment and survivorship statistics, CA Cancer J. Clin., 64, 252, 10.3322/caac.21235 Dekker, 1985, Meningeal involvement in patients with acute nonlymphocytic leukemia Incidence, management, and predictive factors, Cancer, 56, 2078, 10.1002/1097-0142(19851015)56:8<2078::AID-CNCR2820560832>3.0.CO;2-0 Deschler, 2006, Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches, Haematologica, 91, 1513 Douer, 2003, The epidemiology of acute promyelocytic leukaemia, Best Pract. Res. Clin. Haematol., 16, 357, 10.1016/S1521-6926(03)00065-3 Duker, 2002, Chromosome breakage syndromes and cancer, Am. J. Med. Genet., 115, 125, 10.1002/ajmg.10688 Dutcher, 1987, Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival, J. Clin. Oncol., 5, 1364, 10.1200/JCO.1987.5.9.1364 Estey, 1997, Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia, Leukemia, 11, 1661, 10.1038/sj.leu.2400783 Estey, 2014, Acute myeloid leukemia: 2014 update on risk-stratification and management, Am. J. Hematol., 89, 1063, 10.1002/ajh.23834 Falini, 2006, Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features, Blood, 109, 874, 10.1182/blood-2006-07-012252 Farag, 2006, Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Blood, 108, 63, 10.1182/blood-2005-11-4354 Fathi, 2013, Emergence of crenolanib for FLT3-mutant AML, Blood, 122, 3547, 10.1182/blood-2013-10-528992 Fattoum, 2015, Effect of age on treatment decision-making in elderly patients with acute myeloid leukemia, Clin. Lymphoma Myeloma Leuk., 15, 477, 10.1016/j.clml.2015.02.022 Fenaux, 2010, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J. Clin. Oncol., 28, 562, 10.1200/JCO.2009.23.8329 Feng, 2012, Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis, Am. J. Blood Res., 2, 254 Fernandez, 2009, Anthracycline dose intensification in acute myeloid leukemia, N. Engl. J. Med., 361, 1249, 10.1056/NEJMoa0904544 Fischer, 2010, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3, J. Clin. Oncol., 28, 4339, 10.1200/JCO.2010.28.9678 Flasshove, 2000, Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia, Ann. Hematol., 79, 533, 10.1007/s002770000193 Fröhling, 2006, Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B, Blood, 108, 3280, 10.1182/blood-2006-04-014324 Freeman, 2013, Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia, J. Clin. Oncol., 31, 4123, 10.1200/JCO.2013.49.1753 Freireich, 2014, The leukemias: a half-century of discovery, J. Clin. Oncol., 32, 3463, 10.1200/JCO.2014.57.1034 Freireich, 2012, The history of leukemia therapy-a personal journey, Clin. Lymphoma Myeloma Leuk., 12, 386, 10.1016/j.clml.2012.09.014 Gaidzik, 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group, J. Clin. Oncol., 29, 1364, 10.1200/JCO.2010.30.7926 Galanis, 2014, Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants, Blood, 123, 94, 10.1182/blood-2013-10-529313 Gale, 2008, The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia, Blood, 111, 2776, 10.1182/blood-2007-08-109090 Gandhi, 1993, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy, J. Clin. Oncol., 11, 116, 10.1200/JCO.1993.11.1.116 Gardin, 2007, Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial, Blood, 109, 5129, 10.1182/blood-2007-02-069666 Geiger, 2015, New approaches for the immunotherapy of acute myeloid leukemia, Discov. Med., 19, 275 Gilliland, 2002, The roles of FLT3 in hematopoiesis and leukemia, Blood, 100, 1532, 10.1182/blood-2002-02-0492 Grimwade, 2014, Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for prime time?, Blood, 124, 3345, 10.1182/blood-2014-05-577593 Grimwade, 1998, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties, Blood, 92, 2322, 10.1182/blood.V92.7.2322 Grimwade, 2001, The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial, Blood, 98, 1312, 10.1182/blood.V98.5.1312 Grimwade, 2010, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, 116, 354, 10.1182/blood-2009-11-254441 Guièze, 2012, Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study, Am. J. Hematol., 87, 1052, 10.1002/ajh.23311 Hills, 2014, Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol., 15, 986, 10.1016/S1470-2045(14)70281-5 Holowiecki, 2004, Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study, Leukemia, 18, 989, 10.1038/sj.leu.2403336 How, 2012, Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia, Cancer, 118, 6110, 10.1002/cncr.27683 Huang, 1988, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, 72, 567, 10.1182/blood.V72.2.567.567 Im, 2014, DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies, Leukemia, 28, 1774, 10.1038/leu.2014.124 Ivey, 2016, Assessment of minimal residual disease in standard-risk AML, N. Engl. J. Med., 374, 422, 10.1056/NEJMoa1507471 Issa, 2015, Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, Lancet Oncol., 16, 1099, 10.1016/S1470-2045(15)00038-8 2001 Jourdan, 2013, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, 121, 2213, 10.1182/blood-2012-10-462879 Juliusson, 2009, Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry, Blood, 113, 4179, 10.1182/blood-2008-07-172007 Kadia, 2015, Progress in acute myeloid leukemia, Clin. Lymphoma Myeloma Leuk., 15, 139, 10.1016/j.clml.2014.08.006 Kadia, 2015, Toward individualized therapy in acute myeloid leukemia: a contemporary review, JAMA Oncol., 1, 820, 10.1001/jamaoncol.2015.0617 Kadia, 2015, Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia, Br. J. Haematol., 170, 590, 10.1111/bjh.13319 Kampen, 2012, The discovery and early understanding of leukemia, Leuk. Res., 36, 6, 10.1016/j.leukres.2011.09.028 Kantarjian, 2006, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome, Cancer, 106, 1090, 10.1002/cncr.21723 Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J. Clin. Oncol., 30, 2670, 10.1200/JCO.2011.38.9429 Kaushansky, 2010 Kayser, 2011, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood, 117, 2137, 10.1182/blood-2010-08-301713 Kayser, 2015, Minimal residual disease-directed therapy in acute myeloid leukemia, Blood, 125, 2331, 10.1182/blood-2014-11-578815 Kelaidi, 2011, Treatment of acute promyelocytic leukemia with high white cell blood counts, Mediter. J. Hematol. Infect. Dis., 3, e2011038, 10.4084/mjhid.2011.038 Khalade, 2010, Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis, Environ. Health, 9, 31, 10.1186/1476-069X-9-31 Kiyoi, 2015, FLT3 inhibitors: recent advances and problems for clinical application, Nagoya J. Med. Sci., 77, 7 Konopleva, 2014, A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML), Blood, 124, 118, 10.1182/blood.V124.21.118.118 Koreth, 2009, Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials, JAMA, 301, 2349, 10.1001/jama.2009.813 Kottaridis, 2001, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King, Blood, 98, 1752, 10.1182/blood.V98.6.1752 Kuendgen, 2009, Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly, Cancer Treat. Rev., 35, 97, 10.1016/j.ctrv.2008.09.001 Löwenberg, 2009, High-dose daunorubicin in older patients with acute myeloid leukemia, N. Engl. J. Med., 361, 1235, 10.1056/NEJMoa0901409 Löwenberg, 2010, Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study, Blood, 115, 2586, 10.1182/blood-2009-10-246470 Löwenberg, 2013, Sense and nonsense of high-dose cytarabine for acute myeloid leukemia, Blood, 121, 26, 10.1182/blood-2012-07-444851 Larson, 1984, Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia, Am. J. Med., 76, 827, 10.1016/0002-9343(84)90994-X Larson, 2015, Induction therapy for acute myeloid leukemia in younger adults, UpToDate. Lazo, 2003, Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience, Cancer, 97, 2218, 10.1002/cncr.11314 Lee, 2011, A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia, Blood, 118, 3832, 10.1182/blood-2011-06-361410 Lengfelder, 2009, High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG, Leukemia, 23, 2248, 10.1038/leu.2009.183 Levis, 2011, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse, Blood, 117, 3294, 10.1182/blood-2010-08-301796 Ley, 2008, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, Nature, 456, 66, 10.1038/nature07485 Li, 2012, Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML, Leuk. Res., 36, 186, 10.1016/j.leukres.2011.08.014 Lichtenegger, 2015, Immunotherapy for acute myeloid leukemia, Semin. Hematol., 52, 207, 10.1053/j.seminhematol.2015.03.006 Liu, 2015, Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?, Leuk. Lymphoma, 1 Lo Coco, 1999, Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia, Blood, 94, 12, 10.1182/blood.V94.1.12.413a44_12_22 Lo Coco, 2006, Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin, Clin. Adv. Hematol. Oncol., 4, 57 Lo-Coco, 2014, What is the standard regimen for patients with acute promyelocytic leukemia?, Curr. Hematol. Malig. Rep., 9, 138, 10.1007/s11899-014-0206-5 Lo-Coco, 2013, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N. Engl. J. Med., 369, 111, 10.1056/NEJMoa1300874 Ma, 2015, Insights into the all-trans-retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: a meta-analysis, Acta Haematol., 134, 101, 10.1159/000369242 Mandelli, 1997, Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pe, Blood, 90, 1014 Marcucci, 2004, Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461, J. Clin. Oncol., 22, 2410, 10.1200/JCO.2004.03.023 Marcucci, 2010, IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study, J. Clin. Oncol., 28, 2348, 10.1200/JCO.2009.27.3730 Marcucci, 2011, Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications, J. Clin. Oncol., 29, 475, 10.1200/JCO.2010.30.2554 Marcucci, 2013, Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score, J. Clin. Oncol., 32, 548, 10.1200/JCO.2013.50.6337 Mardis, 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome, N. Engl. J. Med., 361, 1058, 10.1056/NEJMoa0903840 Medeiros, 2010, Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience, Blood, 116, 2224, 10.1182/blood-2010-02-270330 Menzin, 2002, The outcomes and costs of acute myeloid leukemia among the elderly, Arch. Intern. Med., 162, 1597, 10.1001/archinte.162.14.1597 Mosna, 2015, Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up, Am. J. Hematol., 10.1002/ajh.24000 Moore, 1960, The central nervous system in acute leukemia: a postmortem study of 117 consecutive cases, with particular reference to hemorrhages, leukemic infiltrations, and the syndrome of meningeal leukemia, Arch. Intern. Med., 105, 451, 10.1001/archinte.1960.00270150105011 Mrózek, 2004, Cytogenetics in acute leukemia, Blood Rev., 18, 115, 10.1016/S0268-960X(03)00040-7 Nazha, 2013, Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia, Am. J. Hematol., 88, 961, 10.1002/ajh.23544 Ohanian, 2013, Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia, Clin. Lymphoma Myeloma Leuk., 13, 93, 10.1016/j.clml.2012.07.008 Ohanian, 2013, Is acute myeloid leukemia a liquid tumor?, Int. J. Cancer, 133, 534, 10.1002/ijc.28012 Ohtake, 2011, Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study, Blood, 117, 2358, 10.1182/blood-2010-03-273243 Oran, 2015, Age and modified european leukemia net classification to predict transplant outcomes: an integrated approach for acute myelogenous leukemia patients undergoing allogeneic stem cell transplantation, Biol. Blood Marrow Transplant., 21, 1405, 10.1016/j.bbmt.2015.03.023 Orfao, 1999, The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements, Haematologica, 84, 405 Orozco, 2012, Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia, Oncology (Williston Park), 26, 706 Ossenkoppele, 2016, Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia, Haematologica, 101, 20, 10.3324/haematol.2015.139105 Ostronoff, 2013, The role of quizartinib in the treatment of acute myeloid leukemia, Expert Opin. Invest. Drugs, 22, 1659, 10.1517/13543784.2013.842973 Padron, 2012, Anthracycline dose intensification in young adults with acute myeloid leukemia, Ther. Adv. Hematol., 3, 17, 10.1177/2040620711427069 Pallavicini, 1984, Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations, Pharmacol. Ther., 25, 207, 10.1016/0163-7258(84)90044-5 Parikh, 2011, Chapter 2. Adult acute myeloid leukemia Park, 2011, Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia, Leuk. Res., 35, 1376, 10.1016/j.leukres.2011.06.003 Park, 2013, High-dose cytarabine consolidation (≥1.5g/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0g/m2) combined with anthracyclines in AML patients who had achieved complete remissions In the first induction by standard 3+7 regimen, Blood, 122, 2692, 10.1182/blood.V122.21.2692.2692 Paschka, 2006, Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study, J. Clin. Oncol., 24, 3904, 10.1200/JCO.2006.06.9500 Paschka, 2010, IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication, J. Clin. Oncol., 28, 3636, 10.1200/JCO.2010.28.3762 Paschka, 2013, Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG), Blood, 121, 170, 10.1182/blood-2012-05-431486 Patel, 2012, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N. Engl. J. Med., 366, 1079, 10.1056/NEJMoa1112304 Patel, 2015, Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?, Am. J. Clin. Oncol., 38, 159, 10.1097/COC.0b013e31828d7536 Pedersen-Bjergaard, 1994, The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation, Blood, 83, 2780, 10.1182/blood.V83.10.2780.2780 Pemmaraju, 2014, Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia, Expert Opin. Invest. Drugs, 23, 943, 10.1517/13543784.2014.911839 Pisciotta, 1955, Fibrinolytic purpura in acute leukemia, Am. J. Med., 19, 824, 10.1016/S0002-9343(55)80028-9 Pogoda, 2006, Smoking and risk of acute myeloid leukemia in adults, Cancer Causes Control, 17, 351, 10.1007/s10552-005-0581-2 Port, 2014, Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis, Ann. Hematol., 93, 1279, 10.1007/s00277-014-2072-6 Pratz, 2010, FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML, Blood, 115, 1425, 10.1182/blood-2009-09-242859 Preston, 1994, Cancer incidence in atomic bomb survivors Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987, Radiat. Res., 137, S68, 10.2307/3578893 Pulsoni, 1998, Acute promyelocytic leukaemia: epidemiology and risk factors: a report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative Group, Eur. J. Haematol., 61, 327, 10.1111/j.1600-0609.1998.tb01096.x Röllig, 2012, Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia, Leuk. Lymphoma, 53, 1062, 10.3109/10428194.2011.637210 Rai, 1981, Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B, Blood, 58, 1203, 10.1182/blood.V58.6.1203.1203 Ratnam, 1994, Leukemia cutis, Dermatol. Clin., 12, 419, 10.1016/S0733-8635(18)30190-6 Rauscher, 2004, Hair dye use and risk of adult acute leukemia, Am. J. Epidemiol., 160, 19, 10.1093/aje/kwh166 Ravandi, 2012, Haematological cancer: gemtuzumab ozogamicin in acute myeloid leukaemia, Nat. Rev. Clin. Oncol., 9, 310, 10.1038/nrclinonc.2012.83 Ravandi, 2009, Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin, J. Clin. Oncol., 27, 504, 10.1200/JCO.2008.18.6130 Ravandi, 2010, Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia, J. Clin. Oncol., 28, 1856, 10.1200/JCO.2009.25.4888 Ravandi, 2012, Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin, Cancer, 118, 2665, 10.1002/cncr.26580 Ravandi, 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation, Blood, 121, 4655, 10.1182/blood-2013-01-480228 Ravandi, 2011, Gemtuzumab ozogamicin: one size does not fit all?the case for personalized therapy, J. Clin. Oncol., 29, 349, 10.1200/JCO.2010.32.2693 Redaniel, 2015, Survival disparities by age and country of diagnosis for patients with acute leukemia, Leuk. Lymphoma, 1 Romagné, 2011, Natural killer cell-based therapies, F1000 Med. Rep., 3, 9, 10.3410/M3-9 Rozovski, 2015, Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia, Leuk. Lymphoma, 56, 1392, 10.3109/10428194.2014.953148 Surveilance, Epidemiology, and End Results Program (SEER), 2015 Santos, 2011, Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia, Cancer, 117, 2145, 10.1002/cncr.25670 Sanz, 2009, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood, 113, 1875, 10.1182/blood-2008-04-150250 Sanz, 2010, Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome, Blood, 115, 5137, 10.1182/blood-2010-01-266007 Schlenk, 2009, Impact of new prognostic markers in treatment decisions in acute myeloid leukemia, Curr. Opin. Hematol., 16, 98, 10.1097/MOH.0b013e3283257adb Schlenk, 2013, Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia, Hematol. Am. Soc. Hematol. Educ. Program, 2013, 324, 10.1182/asheducation-2013.1.324 Schlenk, 2004, Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup, J. Clin. Oncol., 22, 3741, 10.1200/JCO.2004.03.012 Schlenk, 2008, Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N. Engl. J. Med., 358, 1909, 10.1056/NEJMoa074306 Schlenk, 2008, HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR, Biol. Blood Marrow Transplant., 14, 187, 10.1016/j.bbmt.2007.10.006 Schlenk, 2009, Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B, Haematologica, 94, 54, 10.3324/haematol.13378 Schlenk, 2014, Post-remission therapy for acute myeloid leukemia, Haematologica, 99, 1663, 10.3324/haematol.2014.114611 Schnittger, 2005, Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, 106, 3733, 10.1182/blood-2005-06-2248 Sekeres, 2004, Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome, Leukemia, 18, 809, 10.1038/sj.leu.2403289 Sekeres, 2009, Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients, Blood, 113, 28, 10.1182/blood-2008-05-157065 Serve, 1999, Expression and function of Flt3/flk2 in human tumor cell lines, Int. J. Oncol., 14, 765 Shen, 1997, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood, 89, 3354, 10.1182/blood.V89.9.3354 Siegel, 2012, Cancer statistics, CA Cancer J. Clin., 62, 10, 10.3322/caac.20138 Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood, 96, 4075, 10.1182/blood.V96.13.4075 Smith, 2014, Crenolanib is a selective type I pan-FLT3 inhibitor, Proc. Natl. Acad. Sci. U. S. A., 111, 5319, 10.1073/pnas.1320661111 Soignet, 1997, All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study, Cancer Chemother. Pharmacol., 40, S25, 10.1007/s002800051057 Soignet, 1998, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N. Engl. J. Med., 339, 1341, 10.1056/NEJM199811053391901 Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004 Sorror, 2014, Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation, J. Clin. Oncol., 32, 3249, 10.1200/JCO.2013.53.8157 Stein, 2014, AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies, Blood, 124, 115, 10.1182/blood.V124.21.115.115 Stone, 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia, Leukemia, 26, 2061, 10.1038/leu.2012.115 Sudhindra, 2014, FLT3 inhibitors in AML: are we there yet?, Curr. Hematol. Malig. Rep., 9, 174, 10.1007/s11899-014-0203-8 Super, 1993, Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II, Blood, 82, 3705, 10.1182/blood.V82.12.3705.3705 Swerdlow, S.H., Campo, E., Harris, N.L., et al., 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon. Tallman, 2007, Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission, Blood, 110, 409, 10.1182/blood-2006-10-043299 Tassara, 2014, Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients, Blood, 123, 4027, 10.1182/blood-2013-12-546283 Terry, 2005, Occupation, hobbies, and acute leukemia in adults, Leuk. Res., 29, 1117, 10.1016/j.leukres.2005.03.002 The Cancer Genome Atlas Research Network, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N. Engl. J. Med., 368, 2059, 10.1056/NEJMoa1301689 Thiede, 2002, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, Blood, 99, 4326, 10.1182/blood.V99.12.4326 Thol, 2014, Gemtuzumab ozogamicin in acute myeloid leukemia revisited, Expert Opin. Biol. Ther., 14, 1185, 10.1517/14712598.2014.922534 Thomas, 2004, Cigarette smoking and acute leukemia, Leuk. Lymphoma, 45, 1103, 10.1080/10428190310001638904 Tomás, 1996, About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain, Blood, 88, 2357, 10.1182/blood.V88.6.2357.bloodjournal8862357 Tsimberidou, 2006, Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?, Leuk. Lymphoma, 47, 2282, 10.1080/10428190600807178 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Verhaak, 2005, Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance, Blood, 106, 3747, 10.1182/blood-2005-05-2168 Vignetti, M., De Witte, T.M., Suciu, S., et al., n.d. Daunorubicin (DNR) vs mitoxantrone (MTZ) vs Idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem transplantation (SCT): Resu. Vogler, 1992, A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study, J. Clin. Oncol., 10, 1103, 10.1200/JCO.1992.10.7.1103 Walter, 2011, Impact of pretransplantation minimal residual disease, As detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia, J. Clin. Oncol., 29, 1190, 10.1200/JCO.2010.31.8121 Walter, 2013, Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission, Blood, 122, 10.1182/blood-2013-06-506725 Wang, 2013, Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia, PLoS One, 8, e60699, 10.1371/journal.pone.0060699 Warrell, 1993, Acute promyelocytic leukemia, N. Engl. J. Med., 329, 177, 10.1056/NEJM199307153290307 Wiernik, 1992, Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia, Blood, 79, 313, 10.1182/blood.V79.2.313.313 Yan, 2009, IDH1 and IDH2 mutations in gliomas, N. Engl. J. Med., 360, 765, 10.1056/NEJMoa0808710 Yanada, 2005, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis, Leukemia, 19, 1345, 10.1038/sj.leu.2403838 Yanada, 2005, Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis, Cancer, 103, 1652, 10.1002/cncr.20945 Yang, 2014, Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents, Leukemia, 28, 1280, 10.1038/leu.2013.355 Yates, J.W., Wallace, H.J., Ellison, R.R., Holland, J.F., n.d. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57, 485–488. Yeasmin, 2016, Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review, Int. J. Gynecol. Cancer, 18, 1371, 10.1111/j.1525-1438.2007.01185.x Yee, 2014, Phase 1/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (Pts), Blood, 124, 116, 10.1182/blood.V124.21.116.116 Yin, 2012, Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, 120, 2826, 10.1182/blood-2012-06-435669 Zhang, 2008, Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia, J. Natl. Cancer Inst., 100, 184, 10.1093/jnci/djm328